Immortal Dragons, a groundbreaking longevity fund, has announced its innovative approach to investing in radical life extension technologies. With $40 million in assets under management (AUM), the fund is set to transform how capital is deployed to fuel advancements in longevity and healthspan.*
At the heart of Immortal Dragons’ philosophy lies a revolutionary belief: aging and death should not be seen as inevitable but as challenges that can be addressed through scientific innovation. This mindset drives the fund’s investment strategies, prioritizing impactful projects over mere financial returns.
Diverse Investments in Longevity
Immortal Dragons targets multiple areas within the longevity sector, having already backed more than 15 startups leading the way in radical scientific advances. Their investment areas include:
– Replacement & Regeneration: Pioneering research in xenotransplantation and the regeneration of biological components.
– Gene Therapy: Therapeutics that aim to tackle the root causes of aging and age-related diseases.
– 3D Bioprinting: Innovative technologies for printing tissues and organs to aid in therapeutic and regenerative applications.
– Longevity Infrastructure: Establishing foundational ecosystems that foster longevity research, accelerate clinical trials, and provide regulatory support.
Boyang Wang, the founder of Immortal Dragons, emphasizes the fund’s mission: “Whether it’s cutting-edge science or better research environments, we need to see the opportunity for real impact.” He describes the support of “moonshot projects” as essential to pushing the boundaries of innovation, while also stressing the importance of creating conditions conducive to broader success.
Purpose-Driven Capital for Real Change
Immortal Dragons operates with a distinctive single-LP structure, allowing for nimble decision-making and capital deployment to projects that align with the fund’s vision. This model enables the fund to back transformative research that larger venture capital firms may overlook.
“We are a purpose-driven fund, with a strong commitment to valuing impact over economic returns,” Wang noted in a recent interview. His personal commitment to the longevity sector is exemplified by his participation as one of the first in the world to receive Minicircle’s follistatin gene therapy. “This reflects our risk profile and dedication to the cause,” he added.
Advocacy for Global Longevity
Beyond its investment activities, Immortal Dragons is dedicated to advancing global longevity advocacy. The fund is engaged in various educational outreach initiatives, including translating scientific conferences, publishing longevity literature, and sponsoring significant events like Vitalist Bay and ARDD 2025. This multi-faceted approach acknowledges that substantial progress requires both financial support and public engagement.
Prominent academics have praised Immortal Dragons’ advocacy efforts. Professor Peter Lidsky from the City University of Hong Kong remarked on the energy and commitment of the team toward addressing the challenges of aging. Similarly, Aubrey de Grey, president of the LEV Foundation, expressed enthusiasm about the fund’s involvement in the Chinese longevity landscape, which has previously seen limited attention.
Conclusion
Immortal Dragons stands as a pioneering force in the realm of purpose-driven investment. By challenging conventional methods and fostering a new perspective on human healthspan, the fund aims to push the boundaries of science and promote human life extension. As Immortal Dragons continues its mission, it redefines the landscape of longevity investment, inspiring hope for a future where aging is no longer an inevitability but a solvable challenge.
